---
layout: default
title: Activated Charcoal Arnica Montana Whole Collinsoni
parent: 僅模型預測 (L5)
nav_order: 205
evidence_level: L5
indication_count: 0
---

# Activated Charcoal Arnica Montana Whole Collinsoni
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Combination: Insufficient Data for Repurposing Evaluation

## One-Sentence Summary

This submission contains a 14-ingredient homeopathic combination product (including Activated Charcoal, Arnica Montana, Horse Chestnut, Hamamelis virginiana, and Strychnos nux-vomica, among others) with no registered market authorization in Taiwan.
The TxGNN model returned **no predicted indications** for this candidate — likely because the query string was treated as a single unresolvable entity rather than individual active ingredients.
Without a DrugBank ID, original indication data, or any model output, a meaningful repurposing evaluation **cannot be completed at this time**.

---

## Quick Overview

| Item | Content |
|------|---------|
| Drug Queried | Multi-ingredient homeopathic combination (14 components) |
| DrugBank ID | Not available |
| Predicted New Indication | None — TxGNN returned no results |
| Evidence Level | L5 (model prediction only, but no output generated) |
| Taiwan Market Status | Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The Evidence Pack reveals a structural data problem rather than a drug repurposing finding.

The drug query string submitted to TxGNN was the full concatenated INN list of all 14 ingredients (e.g., `"ACTIVATED CHARCOAL; ARNICA MONTANA WHOLE; COLLINSONIA CANADENSIS ROOT; ..."`). TxGNN operates by matching a single drug node in its knowledge graph; a multi-ingredient string like this will not match any node, causing the prediction pipeline to return zero results.

Additionally, no DrugBank ID was resolved (`drugbank_id: null`), which blocks the MOA lookup, indication crosswalk, and DDI queries. Without a DrugBank anchor, the system has no mechanism to characterize the compound or retrieve evidence.

From a pharmacological standpoint, the ingredient profile — Horse Chestnut (*Aesculus hippocastanum*), Hamamelis virginiana, Collinsonia canadensis, and Paeonia officinalis — is characteristic of classical homeopathic formulas targeting **anorectal or venous congestion conditions** (e.g., hemorrhoids, varicose veins). However, this clinical inference cannot be validated without actual regulatory filings or peer-reviewed evidence tied to this specific combination.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The pipeline failed to produce any repurposing candidate because the drug was submitted as a single multi-ingredient string rather than resolved individual components. There is no TxGNN output, no regulatory data, and no safety profile on which to base any clinical recommendation.

**To proceed, the following is needed:**

- **Decompose the submission:** Identify the lead active ingredient (e.g., Horse Chestnut / Aesculus hippocastanum, DrugBank DB01593) and resubmit each component individually through the TxGNN pipeline.
- **Resolve DrugBank IDs:** Map each of the 14 ingredients to their respective DrugBank entries to enable MOA retrieval and DDI analysis.
- **Identify the intended product:** Determine whether this combination corresponds to a known commercial product (e.g., a branded hemorrhoidal homeopathic remedy) to obtain the original indication and label warnings.
- **Rerun the evidence pack:** Once individual DrugBank IDs are available, regenerate clinical trial and literature evidence for each component separately.
- **Consider pipeline-level fix:** The TxGNN query logic should handle multi-ingredient products by splitting on `;` and querying each component independently, then aggregating results.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

